Greencross%20Medical%20Science
107, Ihyeon-ro 30beon-gil, Yongin-si, Gyeonggi-do, 446-770, South Korea
Overview
Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Sustainability
Investment portfolio
- Hemotune
Participated · Series A · Aug 2020
Hemotune is a developer of blood‑purification technology based on nano magnetic beads. The company has built a bead‑based blood‑purification platform intended for treatment of human diseases. Hemotune recently completed a CHF14 million Series B financing. The round was led by Belmondo, with existing investors VP Venture Partners, HEMEX, OCCIDENT and Zürcher Kantonalbank continuing to participate and EFI joining the round. Proceeds from the financing will be used to advance development of the company’s HemoSystem, described as a breakthrough blood‑purification platform based on nano‑engineered magnetic beads. No operating metrics, founding year, or location were provided in the article. Hemotune’s core product, HemoSystem, is a blood purification platform that mixes nanoengineered magnetic beads directly with patients’ blood in a dialysis-like machine and removes beads and bound targets via a magnetic filter before recirculation. The company says the system offers much higher efficiency and precision compared with existing methods. Its first therapy under development is designed to restore adequate immune response in sepsis-associated immunosuppression. Hemotune intends to use the recent funding to complete preclinical development of HemoSystem and to prepare a clinical trial in sepsis, its lead indication. The company highlights sepsis as an underserved global health issue that leads to around 11 million deaths annually. Hemotune was founded in 2017 as a spin-off from ETH Zurich and is being accelerated by Wyss Zurich. The company closed a CHF 7.25 million Series B1 to support these development and clinical-preparation efforts. Hemotune AG is a spin‑off from ETH Zurich (founded 2017) developing HemoSystem, a blood purification platform that mixes nanoengineered magnetic beads directly with patient blood in a dialysis‑like machine. The beads are roughly 300 times smaller than a red blood cell and are coated with selective binding agents to capture disease‑related compounds. While blood flows through a magnetic filter, beads and bound targets are removed before recirculation, with the aim of removing substances that play key roles in immune response and sepsis. With the Series A close hemotune will accelerate preclinical development of HemoSystem and pursue first launches in Europe. The company is incubated at Wyss Zurich and is positioning the technology for septic shock and other indications, with potential relevance to COVID‑19. Hemotune has built industry partnerships to support geographic expansion, notably with Korean partner GCMS for Asian market entry. The company has raised more than CHF 10 million in total since incorporation.
Team
No current team members are available.